|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SNN |
Gene summary for SNN |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SNN | Gene ID | 8303 |
| Gene name | stannin | |
| Gene Alias | SNN | |
| Cytomap | 16p13.13 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | O75324 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8303 | SNN | LZE24T | Human | Esophagus | ESCC | 1.30e-06 | 8.81e-02 | 0.0596 |
| 8303 | SNN | P2T-E | Human | Esophagus | ESCC | 1.59e-26 | 5.19e-01 | 0.1177 |
| 8303 | SNN | P4T-E | Human | Esophagus | ESCC | 6.48e-14 | 4.23e-01 | 0.1323 |
| 8303 | SNN | P5T-E | Human | Esophagus | ESCC | 2.91e-16 | 2.19e-01 | 0.1327 |
| 8303 | SNN | P8T-E | Human | Esophagus | ESCC | 5.56e-09 | 3.28e-02 | 0.0889 |
| 8303 | SNN | P9T-E | Human | Esophagus | ESCC | 8.06e-03 | 3.93e-02 | 0.1131 |
| 8303 | SNN | P10T-E | Human | Esophagus | ESCC | 4.89e-18 | 1.09e-01 | 0.116 |
| 8303 | SNN | P11T-E | Human | Esophagus | ESCC | 1.59e-05 | 1.97e-01 | 0.1426 |
| 8303 | SNN | P12T-E | Human | Esophagus | ESCC | 8.93e-18 | 2.98e-01 | 0.1122 |
| 8303 | SNN | P15T-E | Human | Esophagus | ESCC | 6.21e-08 | 1.62e-01 | 0.1149 |
| 8303 | SNN | P16T-E | Human | Esophagus | ESCC | 7.39e-12 | 1.86e-01 | 0.1153 |
| 8303 | SNN | P17T-E | Human | Esophagus | ESCC | 2.26e-04 | 2.16e-01 | 0.1278 |
| 8303 | SNN | P19T-E | Human | Esophagus | ESCC | 1.24e-02 | 3.37e-01 | 0.1662 |
| 8303 | SNN | P20T-E | Human | Esophagus | ESCC | 7.07e-15 | 3.16e-01 | 0.1124 |
| 8303 | SNN | P21T-E | Human | Esophagus | ESCC | 4.02e-14 | 1.36e-01 | 0.1617 |
| 8303 | SNN | P22T-E | Human | Esophagus | ESCC | 4.90e-15 | 1.65e-01 | 0.1236 |
| 8303 | SNN | P23T-E | Human | Esophagus | ESCC | 2.25e-06 | 1.60e-01 | 0.108 |
| 8303 | SNN | P24T-E | Human | Esophagus | ESCC | 5.88e-05 | 1.04e-01 | 0.1287 |
| 8303 | SNN | P26T-E | Human | Esophagus | ESCC | 7.02e-16 | 1.16e-01 | 0.1276 |
| 8303 | SNN | P27T-E | Human | Esophagus | ESCC | 3.14e-14 | 8.63e-02 | 0.1055 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000963620 | Esophagus | ESCC | response to toxic substance | 150/8552 | 262/18723 | 1.00e-04 | 7.12e-04 | 150 |
| GO:000963618 | Oral cavity | OSCC | response to toxic substance | 137/7305 | 262/18723 | 7.94e-06 | 8.52e-05 | 137 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SNN | SNV | Missense_Mutation | c.126N>G | p.Ser42Arg | p.S42R | O75324 | protein_coding | tolerated_low_confidence(0.06) | probably_damaging(0.928) | TCGA-AO-A0J6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| SNN | SNV | Missense_Mutation | c.21N>A | p.Ser7Arg | p.S7R | O75324 | protein_coding | deleterious_low_confidence(0) | benign(0.037) | TCGA-BH-A1FC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SNN | insertion | Frame_Shift_Ins | novel | c.170_171insCTTGGCACCTGGTTGCTGTGTTCCTGACAAT | p.Lys57AsnfsTer72 | p.K57Nfs*72 | O75324 | protein_coding | TCGA-A8-A0A6-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | epirubicin | CR | ||
| SNN | SNV | Missense_Mutation | rs747411695 | c.119N>A | p.Arg40His | p.R40H | O75324 | protein_coding | deleterious_low_confidence(0) | benign(0) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
| SNN | SNV | Missense_Mutation | novel | c.141N>T | p.Glu47Asp | p.E47D | O75324 | protein_coding | deleterious_low_confidence(0.04) | possibly_damaging(0.874) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SNN | SNV | Missense_Mutation | c.191N>G | p.Gln64Arg | p.Q64R | O75324 | protein_coding | deleterious_low_confidence(0.04) | possibly_damaging(0.728) | TCGA-AP-A054-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD | |
| SNN | SNV | Missense_Mutation | rs775385437 | c.67N>A | p.Ala23Thr | p.A23T | O75324 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.948) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
| SNN | SNV | Missense_Mutation | c.50N>C | p.Val17Ala | p.V17A | O75324 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.822) | TCGA-D1-A177-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SNN | SNV | Missense_Mutation | c.110N>A | p.Arg37Gln | p.R37Q | O75324 | protein_coding | deleterious_low_confidence(0.03) | benign(0.247) | TCGA-L9-A7SV-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | CR | |
| SNN | SNV | Missense_Mutation | c.118N>T | p.Arg40Cys | p.R40C | O75324 | protein_coding | deleterious_low_confidence(0) | benign(0.092) | TCGA-HU-A4GQ-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |